Intellia Therapeutics (NTLA) Expected to Announce Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Intellia Therapeutics to post earnings of ($1.26) per share and revenue of $11.39 million for the quarter.

Intellia Therapeutics Stock Up 8.2 %

Shares of NTLA opened at $8.87 on Thursday. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.18. The firm has a market capitalization of $918.20 million, a PE ratio of -1.63 and a beta of 2.23. The stock's fifty day simple moving average is $8.44 and its 200-day simple moving average is $11.66.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group reaffirmed a "sell" rating and set a $9.00 price target on shares of Intellia Therapeutics in a research note on Friday, February 28th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. Truist Financial dropped their price objective on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Finally, Oppenheimer dropped their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a report on Monday, January 13th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $36.68.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.